In SCLC, it has been reported that CDKN2A mRNA levels in 357 SCLC cases were notably higher than those in the control group, and patients with higher CDKN2A expression had considerably poorer OS rates compared to those with lower CDKN2A levels (47). This evidence concerns the gene CDKN2A and small cell lung carcinoma.